Lyell Historical Balance Sheet
| LYEL Stock | USD 0.92 0.01 1.10% |
Trend analysis of Lyell Immunopharma balance sheet accounts such as Total Current Liabilities of 41.7 M provides information on Lyell Immunopharma's total assets, liabilities, and equity, which is the actual value of Lyell Immunopharma to its prevalent stockholders. By breaking down trends over time using Lyell Immunopharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Lyell Immunopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lyell Immunopharma is a good buy for the upcoming year.
Lyell |
About Lyell Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Lyell Immunopharma at a specified time, usually calculated after every quarter, six months, or one year. Lyell Immunopharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lyell Immunopharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lyell currently owns. An asset can also be divided into two categories, current and non-current.
Lyell Immunopharma Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Lyell Immunopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lyell Immunopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Lyell Immunopharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lyell Immunopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Lyell Immunopharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Lyell Immunopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.At this time, Lyell Immunopharma's Cash is quite stable compared to the past year. Non Current Assets Total is expected to rise to about 305.5 M this year, although the value of Other Liabilities will most likely fall to about 3.5 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 67.8M | 67.7M | 63.2M | 61.8M | Total Assets | 1.1B | 937.6M | 750.0M | 941.4M |
Lyell Immunopharma balance sheet Correlations
Click cells to compare fundamentals
Lyell Immunopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.